Evidence map›Paper›PMID 35087718›Full record

ArticleBioImpacts : BI2022

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Efthymia-Iliana Matthaiou, Yi Guo, Jaleh Barar, Raphael Sandaltzopoulos, Lana E Kandalaft, Chunsheng Li, George Coukos, Yadollah Omidi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioImpacts : BI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 5 countries.

Efthymia-Iliana MatthaiouOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.ORCID https://orcid.org/0000-0002-0907-0203
Yi GuoOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Jaleh BararOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.ORCID https://orcid.org/0000-0002-0105-919X
Raphael SandaltzopoulosDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
Lana E KandalaftLudwig Institute for Cancer Research, Lausanne and University of Lausanne, Lausanne, Switzerland.
Chunsheng LiOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
George CoukosOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Yadollah OmidiOvarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.ORCID https://orcid.org/0000-0003-0067-2475
Cancer Research Center · USDemocritus University of Thrace · GRLudwig Cancer Research · CHUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD248NanomedicineShikoninTargeted therapyTumor endothelial marker 1, endosialinTumor vasculature

Identifiers

PMID35087718
PMCPMC8783079
OpenAlexW4210547813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.